康艾注射液联合吉西他滨治疗老年非小细胞肺癌临床分析

摘要

目的 研究康艾注射液联合吉西他滨(GEM)化疗对老年非小细胞肺癌(NSCLC)患者近期疗效、生活质量(QOL)、毒副反应的影响.方法 43 例ⅢB～Ⅳ期老年NSCLC 患者,随机分为治疗组和对照组;所有患者均采用GEM 化疗,1 200 mg/m2,第1、8 d;治疗组在每个疗程的第1 d 至第14 d 以康艾注射液50 ml/m2加入生理盐水250ml 静脉点滴;两组均21 d 为1 疗程;连用2 疗程后,评价近期疗效、QOL 和毒副反应;反映QOL 的指标包括KPS评分、疼痛程度和肺癌治疗功能评价量表(FACT-L).结果 两组总有效率差异无统计学意义(22.73% vs.19.05%,χ2 =0.0879,P >0.005);治疗组的KPS 评分在治疗后显著升高(P <0.05),提高的幅度显著高于对照组(12.27±6.85 vs 3.81±8.05,P <0.01);应用FACT-L 进行评估,亦显示治疗组的改善情况优于对照组(12.27±6.85 vs 3.81±8.05,P<0.01);治疗组中治疗相关的血液系统毒性(血小板减少,白细胞减少,红细胞减少)显著低于对照组(P <0.05).结论 康艾注射液可以减轻老年NSCLC 患者GEM 化疗期间的毒副反应,改善生活质量.%Objective To investigate the short-term therapeutic effect, quality of life (QOL) and adverse effect of Kang'ai injection plus gemcitabine (GEM) for elderly patients with non-small cell lung cancer (NSCLC). Methods Forty-three elderly patients with NSCLC of ⅢB ~Ⅳ stage were randomly divided into treatment group and control group. All of the cases received GEM 1200mg/m2 on day 1 and 8. In every course of treatment, patients of treatment group additionally received 50 ml Kang'ai injection through intravenous infusion from day 1 to day 14. The treatment was repeated for every 21 days. After two courses of treatment, efficacy, QOL and toxicity were observed. QOL was reflected through the score of KPS, the degree of pain and functional assessment of cancer therapy-lung (FACT-L). Results The difference of response rate between the two groups was not significant (22.73% vs 19.05%, x2=0.0879, P>0.05). In treatment group, the score of KPS was enhanced more significantly than that in control group (P<0.05), and the degree of enhancement was markedly higher than that in control group (12.27±6.85 vs 3.81±8.05,P<0.01). In addition, treatment group also showed more improvement than control group through FACT-L (12.27± 6.85 vs 3.81±8.05, P<0.0l). In treatment group, the treatment related toxicities in blood system, including thrombopenia, leucopenia and ery-thropenia, were also markedly less than those in control group (P<0.05). Conclusion Kangai injection may reduce the adverse effect and enhance QOL in elderly NSCLC patients received GEM chemotherapy.